The effect of COPD self-management support services on changes in physical activity

JRCT ID: jRCT1050240002

Registered date:03/04/2024

Basic Information

• Recruitment status: Recruiting
• Health condition(s) or Problem(s) studied: chronic obstructive pulmonary disease
• Date of first enrollment: 11/04/2024
• Target sample size: 40
• Study type: Observational

Outcome(s)

• Primary Outcome: Change in physical activity using tri-axial accelerometer before and after the use of COPD Self-Management Support Service

Secondary Outcome

1. Rate of use of manuals and application support when installing applications and their effectiveness. The use of manuals or application support to complete the installation is defined as valid.
2. Usage rate and satisfaction with COPD self-management support service
3. Physician's assessment of subject's use of COPD Self-Management Support Service on researcher's side.
4. Reasons for discontinuation
5. Relationship between the results of COPD imaging analysis, respiratory function, body composition, muscle mass, and other characteristics of the study subjects and the effectiveness of service use
6. Relationship between application input content and measurement results by tri-axial accelerometer

Key inclusion & exclusion criteria

• Age minimum: >= 65age old
• Age maximum: Not applicable

Include criteria

COPD patients attending the Respiratory Medicine Outpatient Clinic at Shiga University of Medical Science Hospital during the study period.

Those who are age 65 years or older at the time of enrollment.
Those who have a history of smoking. However, the number of years and number of cigarettes smoked will not be asked ab
out smoking history.
Gender is not a factor.
Those who own and use a smartphone on which the COPD Self-Management Support Service application can be installed.
The attending physician has determined that the patient is capable of wearing the tri-axial accelerometer and entering the patient's medical records into the smartphone application.
Those who have agreed to participate in this study by signing a consent form.

• Exclude criteria: none

Related Information

• Primary Sponsor: Nakano Yasutaka
• Source(s) of Monetary Support: Teijin Pharma Limited